14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ospemifene is a selective estrogen receptor modulator recently approved by the FDA for the treatment postmenopausal women experiencing moderate-to-severe dyspareunia and by the EMA for the treatment of moderate-to-severe symptomatic genitourinary syndrome of menopause (GSM) in women who are not suitable candidates for local vaginal estrogen therapy.

          Related collections

          Author and article information

          Journal
          Expert Opin Drug Metab Toxicol
          Expert opinion on drug metabolism & toxicology
          Informa UK Limited
          1744-7607
          1742-5255
          Oct 2016
          : 12
          : 10
          Affiliations
          [1 ] a Academic Unit of Obstetrics and Gynaecology , IRCCS AOU San Martino - IST , Genova , Italy.
          [2 ] b Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI) , University of Genova , Genova , Italy.
          Article
          10.1080/17425255.2016.1218847
          27476551
          3533cca4-add9-438f-bc21-bf86eb0cd1c1
          History

          Atrophy,clinical efficacy,dyspareunia,genitourinary syndrome,menopause,ospemifene,pharmacodynamics,pharmacokinetics

          Comments

          Comment on this article